Start with your question. Search first, choose the closest subject and keep personal details private. Posting guidelines
Notifications
Clear all
Peptides & Research Compounds
2
Posts
2
Users
0
Reactions
207
Views
Topic starter
16/09/2019 5:11 pm
Meta-level question: how do you evaluate evidence for hexarelin when the human data is thin and most trials are small?
Most of the popular protocols are borrowed from clinical populations and applied to healthy people without comment.
Loose evidence is not the same as no evidence and people overcorrect in both directions.
There is a serious question about whether the studied form matches what is sold, and nobody in a thread can answer it.
I would rather have a narrow conclusion and be right than a broad one and be interesting.
Where does the human data stop and the extrapolation start?
16/09/2019 6:37 pm
Underdosing and tolerance are indistinguishable from the inside, and everyone picks the flattering explanation.